TOVX: Gunggung utang perusahaan Theriva Biologics

Theriva Biologics, Inc. (TOVX) minimizes technological threats by developing tools to support microflora and combat neoplasms. The development of viral drugs relies on partnerships with scientific institutes, which increases the likelihood of acquisition by market behemoths. The confirmed price history on this chart reflects the current level of 0.00, while the business funds costly research using existing cash reserves.

TOVX Utang perusahaan Theriva Corp (28.04.2023 - 31.10.2026)

Rincian analitis perusahaan Theriva Biologics (TOVX)

- rega saham lan target rega konsensus:

Kurs saham Theriva Corp|TOVX - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Biji pasar Synthetic Biologics|TOVX - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Nilai Aset Bersih saben Saham Theriva Biologics|TOVX - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku therivabio.com|TOVX - Aset Agregat Perusahaan

- indikator beban kredit lan likuiditas emiten:

Utang marang Modal Theriva Biologics, Inc.|TOVX - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas Theriva Biologics Inc|TOVX - Gunggung utang perusahaan|Utang-utang marang nilai buku Synthetic Biologics|TOVX - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Theriva Biologics|Koefisien jangkoan perantara therivabio.com

- data bathi lan kelipatan valuasi:

TOVX - Bathi resik perusahaan

Ringkesan analitik perusahaan:TOVX - Theriva Corp

The development of VCN-01 immunotherapy requires significant capital expenditures for safety and inhibitor combinations, making the financial stability of Theriva Biologics, Inc. (TOVX) critical. The total volume of loans and bonds, reflected in the company's debt history, allows for an assessment of the balance between leverage and business viability, helping investors determine the risk of default or the potential for growth in shareholder returns.

Karo sapa Theriva Biologics, Inc. saingan